OTC Watch

All stocks / BCLI

BRAINSTORM CELL THERAPEUTICS INC. BCLI

Brainstorm Cell Therapeutics (BCLI): shares outstanding up 29% in a year, convertible notes mentioned in an 8-K in January 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated floatCostly financing OTCQBNew York, USA
Live quote on OTC Markets

Market listing

Full name
BRAINSTROM CELL THERAPEUTICS
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
www.brainstorm-cell.com
Source: Stockwatch, 2026-11-17

News headlines

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-16 16:01 · News Release
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
2026-08-24 08:15 · News Release
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-14 16:00 · News Release
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
2026-07-28 08:00 · News Release
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
2026-06-02 09:00 · News Release
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
2026-05-28 07:45 · News Release
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
2026-05-19 08:00 · News Release
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 16:05 · News Release
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
2026-03-31 16:01 · News Release
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
2026-02-26 06:22 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($10,307,000)
What it means

It spends more than it earns

Under strain

The company lost $10.3 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$29,000
Net cash used in operating activities
($6,975,000)
What it means

The cash could run out soon

Under strain

It had $29,000 in the bank and used about $581,250 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$1,022,000
Total liabilities
$11,007,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $1 million. Its debts and unpaid bills add up to $11 million. That is about $10.77 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-11-11

Shares outstanding rose from 11,034,775 (2025-11-11) to 14,259,377 (2026-11-11), up 29%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-11-11

Estimated float about 11,390,773 shares as of 2026-11-11: 14,259,377 outstanding minus 2,868,604 held by 5 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-01-09

8-K filed 2026-01-09 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-12-31
11.0M
2026-03-27
11.0M
2026-03-31
11.0M
2026-05-11
11.0M
2026-06-30
11.0M
2026-08-11
11.0M
2026-09-30
14.3M
2026-11-11
14.3M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 8-KFORM 8-K
2026-11-16 10-Q10-Q
2026-08-14 8-KFORM 8-K
2026-08-14 10-Q10-Q
2026-07-30 8-KFORM 8-K
2026-07-28 4OWNERSHIP DOCUMENT
2026-07-28 4OWNERSHIP DOCUMENT
2026-06-03 3OWNERSHIP DOCUMENT
2026-06-02 EFFECT
2026-06-01 CORRESP
2026-05-29 4OWNERSHIP DOCUMENT
2026-05-29 4OWNERSHIP DOCUMENT

Common questions about BCLI

Does BCLI file reports with the SEC?

Yes. Brainstorm Cell Therapeutics files with the SEC under company number 0001137883. The most recent filing we hold is a 8-K dated 2026-11-16.

Source record

How many BCLI shares are outstanding?

14,259,377 shares as of 2026-11-11, as reported to the SEC. That is up 29% from 11,034,775 on 2025-11-11.

Source record

Has BCLI filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Brainstorm Cell Therapeutics?

Officers named in its insider filings: Chaim Lebovits (President & CEO), Alla Patlis (See Remarks) and Peter Joe Pitts (Executive Chairman).

Source record

Is Brainstorm Cell Therapeutics making money?

The company lost $10.3 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record